"Designing Growth Strategies is in our DNA"
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder leading to weakness and loss of sensation in legs and arms. It occurs due to the improper reaction of the body’s immune system and damaging myelin sheath. Myelin sheath surrounds the peripheral nerves system and acts as an insulator for the nerves to conduct impulses properly. Symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP) includes tingling, numbness or altered feeling, which often begins in hand and feet, weakness in arms and legs, fatigue, muscle pain, and others.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is more prominently observed in men than in women. The active government support through awareness programs and drug approvals is expected to positively impact the global chronic inflammatory demyelinating polyneuropathy therapeutics market. Furthermore, the FDA approval for Hizentra, a subcutaneous immunoglobulin manufactured by CSL Behring in March 2018, is estimated to accelerate the demand for chronic inflammatory demyelinating polyneuropathy drugs.
To gain extensive insights into the market, Request for Customization
The rising prevalence of chronic inflammatory demyelinating polyneuropathy increased R&D spending, and strategic research collaborations between pharmaceutical industries are the factors attributed to the growth in the global chronic inflammatory demyelinating polyneuropathy therapeutics market.
Also, active government support in creating awareness about rare neurological diseases and the expected launch of potential pipeline drugs candidates are anticipated to further fuel the global chronic inflammatory demyelinating polyneuropathy therapeutics market. For example, Pfizer Inc. has initiated the phase 1 clinical study for PF-06755347, a recombinant immunomodulatory drug candidate for the treatment of chronic inflammatory demyelinating polyneuropathy.
However, high pricing of the approved drugs and presence of limited treatment options are the major factors that can restrain the growth in the global chronic inflammatory demyelinating polyneuropathy therapeutics market.
Some of the major companies that are present in the global chronic inflammatory demyelinating polyneuropathy therapeutics market are CSL Behring, ADMA Biologics, Grifols, S.A., Shire, Pfizer Inc., GeNeuro SA, Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, AbbVie, Inc., Mitsubishi Tanabe Pharma Corporation, and others.
By Drug Type
By Route of Administration
By Distribution Channel
· Hospital Pharmacy
· Retail Pharmacy
· Online Pharmacy
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Based of drug type, the immunoglobulin segment is anticipated to have exponential growth in the global chronic inflammatory demyelinating polyneuropathy therapeutics market over the forecast period owing to the new product launch, rapid adoption of both intravenous and subcutaneous immunoglobulins for the treatment of chronic inflammatory demyelinating polyneuropathy, and emerging government guidelines.
North America is projected to dominate the global chronic inflammatory demyelinating polyneuropathy therapeutics market in the forecast duration owing to the increase in incidence and prevalence of the chronic inflammatory demyelinating polyneuropathy. According to the CIDP Foundation International, chronic inflammatory demyelinating polyneuropathy (CIDP) affects about 8.9% per 100,000 people every year in North America, which is likely to propel the growth of global chronic inflammatory demyelinating polyneuropathy therapeutics market. Europe and Asia Pacific are expected to register a considerable growth rate owing to the active government support, developing healthcare infrastructure, and growing emphasis by healthcare organizations and government towards the development of the new therapeutics on chronic inflammatory demyelinating polyneuropathy.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry